324 related articles for article (PubMed ID: 22689681)
21. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
22. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
24. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
25. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
26. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.
Metzeler KH; Maharry K; Kohlschmidt J; Volinia S; Mrózek K; Becker H; Nicolet D; Whitman SP; Mendler JH; Schwind S; Eisfeld AK; Wu YZ; Powell BL; Carter TH; Wetzler M; Kolitz JE; Baer MR; Carroll AJ; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2013 Oct; 27(10):2023-31. PubMed ID: 23765227
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
[TBL] [Abstract][Full Text] [Related]
28. Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.
Silva FP; Almeida I; Morolli B; Brouwer-Mandema G; Wessels H; Vossen R; Vrieling H; Marijt EW; Valk PJ; Kluin-Nelemans HC; Sperr WR; Ludwig WD; Giphart-Gassler M
Haematologica; 2009 Nov; 94(11):1546-54. PubMed ID: 19773259
[TBL] [Abstract][Full Text] [Related]
29. Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified.
You E; Cho YU; Jang S; Seo EJ; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park YM; Lee JK; Park CJ
Am J Clin Pathol; 2017 Jul; 148(1):64-72. PubMed ID: 28927163
[TBL] [Abstract][Full Text] [Related]
30.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
31. AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.
Alpermann T; Haferlach C; Eder C; Nadarajah N; Meggendorfer M; Kern W; Haferlach T; Schnittger S
Leuk Res; 2015 Mar; 39(3):265-72. PubMed ID: 25592059
[TBL] [Abstract][Full Text] [Related]
32. [Clinical Characteristics of Acute Myeloid Leukemia Patients with RUNX1 Gene Mutation].
Ni ZF; Ma LJ; Shi LL; Shen PL; Zhao JQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1411-1416. PubMed ID: 34627418
[TBL] [Abstract][Full Text] [Related]
33. Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.
Al-Kzayer LF; Sakashita K; Al-Jadiry MF; Al-Hadad SA; Uyen le TN; Liu T; Matsuda K; Abdulkadhim JM; Al-Shujairi TA; Matti ZI; Hasan JG; Al-Abdullah HM; Inoshita T; Kamata M; Sughayer MA; Madanat FF; Koike K
Pediatr Blood Cancer; 2014 Nov; 61(11):1980-5. PubMed ID: 25066867
[TBL] [Abstract][Full Text] [Related]
34. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.
Schnittger S; Dicker F; Kern W; Wendland N; Sundermann J; Alpermann T; Haferlach C; Haferlach T
Blood; 2011 Feb; 117(8):2348-57. PubMed ID: 21148331
[TBL] [Abstract][Full Text] [Related]
35. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML.
Simon L; Spinella JF; Yao CY; Lavallée VP; Boivin I; Boucher G; Audemard E; Bordeleau ME; Lemieux S; Hébert J; Sauvageau G
Blood; 2020 May; 135(21):1882-1886. PubMed ID: 32315381
[TBL] [Abstract][Full Text] [Related]
36. Integrative analysis of RUNX1 downstream pathways and target genes.
Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael C; Ritchie ME; Schütz F; Cannon P; Liu M; Shen X; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS
BMC Genomics; 2008 Jul; 9():363. PubMed ID: 18671852
[TBL] [Abstract][Full Text] [Related]
37. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
[TBL] [Abstract][Full Text] [Related]
38. Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
Dicker F; Haferlach C; Kern W; Haferlach T; Schnittger S
Blood; 2007 Aug; 110(4):1308-16. PubMed ID: 17485549
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia.
Fu Y; Zhu H; Wu W; Xu J; Chen T; Xu B; Qian S; Li J; Liu P
Leuk Lymphoma; 2014 Feb; 55(2):371-7. PubMed ID: 23713453
[TBL] [Abstract][Full Text] [Related]
40. RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.
Rehman A; Akram AM; Chaudhary A; Sheikh N; Hussain Z; Alsanie WF; Rehman RA; Hameed N; Saleem T; Zafar A; Absar M; Iqbal Z; Alhazmi A; Baeshen HA; Mohammedsaleh ZM; Qamer S; Sayed S; Gaber A
Saudi J Biol Sci; 2021 Sep; 28(9):4845-4851. PubMed ID: 34466057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
